Sun Pharma's Leqselvi shows sustained hair regrowth through two years in alopecia areata
India's Sun Pharmaceutical Industries (NSE: SUNPHARMA; BSE: 524715) presented new two-year data on Leqselvi (deuruxolitinib) at the European Academy of Dermatology and Venereology (EADV) Congress 2026, across seven presentations including a featured oral presentation on long-term safety and a poster on durability of hair regrowth in adults with severe alopecia areata (AA).
The featured oral presentation, drawing on a European open-label extension study, found Leqselvi's safety profile remained generally consistent with prior clinical experience through up to two years of treatment at the US Food and Drug Administration (FDA)-approved dose of 8mg twice daily.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Biotechnology
| Headless Content Management with Blaze